Christopher John Kenney

Christopher John Kenney discloses dealings in Xenon Pharmaceuticals Inc. to SEC (Form 4). The record holds 6 filings, for trades running from 21 January 2022 to 28 August 2026.

Both buying and selling appear: 1 purchase worth €18k, against 3 sales worth €388k. Netting one side against the other leaves €370k of net selling. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Other entries cover 2 option exercises. In 2026 alone, the filings show no purchases and 2 sales.

The latest filing, published on 31 August 2026, reports an open-market sale of €329k in Xenon Pharmaceuticals Inc. The last insider purchase was made public on 21 January 2022, 1,731 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. US insiders must file a Form 4 within two business days of a trade. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.